论文部分内容阅读
新京报9月21日讯新三板是个产生“奇迹”的地方,仁会生物,一家连续多个报告期零营收的公司,市值一度达到80亿元,拿下新三板药企市值第二的交椅。这有赖于机构投资者的追捧。依靠仍在研发之中的药物,过去半年多时间里,仁会生物完成四次定增,总融资额4亿元。与当初承诺的用途不同,4亿元的募集资金,多数被仁会生物投入了资本市场。半年报显示,今年上半年,这家没有营收的公司,依靠投资等收益,取得了1亿多元的净利润。从仁会生物披露的资料显示,现在已是其主
Beijing News September 21 News The new board is a “miracle” place, Renhe biological, a number of consecutive zero-revenue reporting company, the market capitalization reached 80 billion yuan at one time, won the new three-plate drug companies market capitalization Second place. This depends on institutional investors sought after. Relying on drugs still under research and development, Renhe Bio has completed four fixed increases over the past six months or so with a total financing amount of 400 million yuan. Different from the original promise, the 400 million yuan of raised funds, the majority of benevolence creatures invested in the capital market. Semi-annual report shows that in the first half of this year, this company has no revenue, relying on investment income, made more than 100 million yuan of net profit. According to information disclosed by Renhe Bio, it is now the main one